The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 5, 2009, Pages 331-335

  Montagnana, Martina ^a,b   Lippi, Giuseppe ^a   Ruzzenente, Orazio ^a   Bresciani, Valentina ^b   Danese, Elisa ^a   Scevarolli, Silvia ^b   Salvagno, Gian Luca ^a   Giudici, Silvia ^b   Franchi, Massimo ^b   Guidi, Gian Cesare ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

CA125; Cancer markers; HE4; Ovarian cancer; Pelvic mass

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PELVIS TUMOR; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

CASE-CONTROL STUDIES; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PROTEINS; ROC CURVE;

EID: 70349528266     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20340     Document Type: Article

References (26)

1. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-179.
2. Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008;113:733-742.
3. Heitz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet 2006;95:S161-S192.
4. Dunleavey R. Importance of early diagnosis in managing ovarian cancer. Nurs Times 2006;102:28-29.
5. Evans J, Ziebland S, McPherson A. Minimizing delays in ovarian cancer diagnosis: An expansion of Andersen's model of "total patient delay". Fam Pract 2007;24:48-55.
6. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003;63:2913-2922. (Pubitemid 36667164)
7. Grisaru D, Hauspy J, Prasad M, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep 2007;18:1347-1356.
8. Berry NB, Cho YM, Harrington MA, Williams SD, Foley J, Nephew KP. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 2004;92:896-904. (Pubitemid 38251394)
9. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-2169. (Pubitemid 40490123)
10. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-3700. (Pubitemid 36793054)
11. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-382.
12. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-853. (Pubitemid 43780455)
13. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S161-S192.
14. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-892.
15. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
16. Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337. (Pubitemid 12235035)
17. Rustin GJ, Bast Jr RC, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919-3926.
18. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-929. (Pubitemid 20340625)
19. Bast Jr RC, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res 2007;174:91-100.
20. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-277. (Pubitemid 41502830)
21. Moore RG, Brown AK, Miller MG, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-408.
22. Ayhan A, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand 2007;86:484-490.
23. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-27375. (Pubitemid 37410652)
24. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. J Biol Chem 1992;267:6171-6177.
25. Boshell M, Lalani E-N, Pemberton L, Burchell J, Gendler S, Taylor-Papadimitriou J. The product of the human MUC1 gene when secreted by mouse cells transfected with the full length. cDNA lacks the cytoplasmic tail. Biochem Biophys Res Commun 1992;185:1-8.
26. Moore RG, Brown AK, Miller MG, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196-201.